PI Industries , a leading agrochemical and specialty chemicals company, held its 78th Annual General Meeting (AGM) on August 14, 2025, through video conferencing. The company announced that all 10 resolutions presented to shareholders were passed with the required majority, demonstrating strong shareholder support across various categories.

Key Approvals and Appointments

Shareholders approved several important resolutions, including:

• Adoption of financial statements for the year ended March 31, 2025
• Confirmation of interim dividend of Rs. 6.00 per share and declaration of final dividend of Rs. 10.00 per share
• Re-appointment of Mayank Singhal as Vice Chairperson & Managing Director
• Re-appointment of Rajnish Sarna as Joint Managing Director
• Re-appointment of Lisa J. Brown as Independent Director
• Appointment of Vegulaparanan Kasi Viswanathan as Independent Director
• Appointment of Dr. Tanjore Soundararajan Balganesh as Non-Executive Non-Independent Director

Financial Performance

The company reported strong financial results for the fiscal year 2024-25:

Dividend Declaration

The Board of Directors recommended a final dividend of Rs. 10.00 per share (1000%) in addition to the interim dividend of Rs. 6.00 per share (600%) already paid, subject to shareholder approval at the AGM.

Strategic Initiatives and Growth

During the fiscal year, PI Industries made significant strides in its growth strategy:

• Launched 6 new products in Exports and 7 new Agri brands in India
• Commercialized 7 new molecules, including in Electronic & Performance Chemicals
• Filed 44 patents and advanced its first proprietary A.I. (Active Ingredient) insecticide, PIOXANILIPROLE, to Phase-3 trials across key markets
• Invested approximately Rs. 130 crore in capex for the Pharma vertical to enhance integrated R&D-to-manufacturing capabilities

Acquisition and Expansion

PI Industries completed the acquisition of Plant Health Care PLC on August 20, 2024, through its wholly-owned subsidiary. This acquisition is expected to accelerate the company's biologicals platform and expand its global reach.

Sustainability and ESG Efforts

The company was featured in the S&P Global Sustainability Yearbook for the second consecutive year, ranking in the top three percent of chemical companies globally. PI Industries has adopted IFRS S1 and S2 standards with a "Climate-First" approach in its Integrated Report.

Chairman's Statement

Narayan K Seshadri, Chairman of PI Industries, addressed the shareholders, highlighting the company's resilience and strategic focus on innovation-led execution and disciplined growth. He emphasized the company's theme for FY2024-25, "Empowering through Innovation: Where Science Meets Life," which captures the intent to turn scientific excellence into real-world solutions that improve lives, strengthen food security, and support a healthier planet.

The successful AGM and the passage of all resolutions reflect the confidence of shareholders in PI Industries' management and future prospects. The company continues to focus on diversification, innovation, and sustainable growth in the agrochemical and specialty chemicals sectors.

PI Industries , a leading agrochemical and pharmaceutical company, has reaffirmed its margin expectations for the fiscal year 2026 despite facing headwinds in the first quarter. This information was shared during a recent conference call update, highlighting the company's confidence in its long-term strategy and market position.

Q1 Financial Performance

PI Industries reported a consolidated revenue of ₹19,005.00 crore for the quarter, marking an 8% year-on-year decline from ₹20,689.00 crore in the same quarter last year. Despite the revenue dip, the company managed to maintain a robust EBITDA margin of 27%, showcasing its operational efficiency in challenging market conditions.

Key financial highlights for Q1 include:

Segment Performance

The company's performance across its two main segments showed mixed results:

1. Agro Chemicals: This segment, which includes agchem exports, domestic agri brands, and biologicals, reported revenue of ₹18,287.00 crore. Despite a slight decline, it remains the primary revenue driver for PI Industries.

2. Pharma: The pharmaceutical segment showed significant growth, with revenue increasing to ₹723.00 crore, marking a substantial 186% year-on-year growth. This rebound in the pharma sector is a positive sign for the company's diversification efforts.

Strategic Developments

PI Industries continues to focus on innovation and expansion:

• Commercialized 2 new products in Exports and 2 in Domestic Agri Brands
• New products in Agchem Exports growing approximately 46% year-on-year
• India's first discovery molecule filed for registration

Outlook and Management Commentary

Despite the short-term challenges, PI Industries' management remains optimistic about the company's prospects. The decision to maintain margin expectations for FY26 suggests confidence in the company's ability to navigate current market dynamics and capitalize on growth opportunities.

Mayank Singhal, Vice Chairman & Managing Director of PI Industries, commented on the results, stating, "Our Q1 performance was broadly in line with our plan, and we are expecting to accelerate in the second half of the fiscal year. The maintained margin outlook for FY26 reflects our strong market position and operational efficiencies."

Conclusion

While PI Industries faced some headwinds in Q1, the company's maintained margin expectations for FY26 and strong growth in its pharma segment indicate resilience in its business model. The focus on new product commercialization and strategic initiatives in both agro chemicals and pharmaceuticals positions PI Industries well for future growth. Investors and industry observers will be keenly watching the company's performance in the coming quarters to see if it can meet its margin expectations and return to revenue growth.